![Elevation Oncology, Inc. logo](/logos/ELEV.webp)
Elevation Oncology, Inc.
NASDAQ:ELEV
Overview | Financials
Company Name | Elevation Oncology, Inc. |
Symbol | ELEV |
Currency | USD |
Price | 0.625 |
Market Cap | 36,941,750 |
Dividend Yield | 0% |
52-week-range | 0.363 - 5.83 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Joseph J. Ferra Jr. |
Website | https://elevationoncology.com |
An error occurred while fetching data.
About Elevation Oncology, Inc.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD